At its booth in Hospitalar 2023, ABIMED created an interesting meeting point for its members, with many possibilities for networking and business generation, including the cocktail for stakeholders on the 24th day. The space had three sponsors in an unprecedented model: Biomedial, Fujifilm, and Karls Stors. The initiative was very successful and the entity intends to continue the model in future editions of the Fair, opening up opportunities for a larger number of members.

The ABIMED booth also hosted strategic panels. Computational modeling was the highly innovative concept addressed by Priscilla Lemes, Regulatory Affairs Specialist at Edwards Lifesciences.  She focused on the future of the regulatory landscape with the rise of In Silico Clinical Trials (ISCT). It is the use of computers to simulate and study complex systems using mathematics, physics, and computer science. Using the computer model, In Silico clinical trials involve virtual patients, rather than real patients, and have demonstrated their effectiveness. “In Silico clinical trials help bring treatment to patients more quickly, reducing costs for the market,” pointed out the specialist.

Another highlight of the booth was the presentation of the unprecedented study about the medical devices market in Brazil, ordered by ABIMED to IN3 Inteligência. Leandro Henrique Rocha dos Santos, director and partner at IN3, revealed that the market moved US$ 7.4 billion in 2022 (but it can be six times larger, according to the consultancy’s projection) and shows a trend of stability in the coming years. He also listed some challenges that the sector is facing at the moment, such as the discussion around the ANS taxative/exemplifying list, the recently defined salary floor for Nursing, and the progressive increase of chronic diseases. These are all factors that put strong pressure on the segment. The research also brought a projection of 6% growth in jobs generated in the sectors represented by ABIMED for this year.

Also at ABIMED’s request, the law firm SPLaw Advogados made an analysis of the New Law on Bidding and Administrative Contracts (NLLC) – Law 14.133/21, highlighting some opportunities and points of attention. Attorney Benny Spiewak warned that the new law imposes limitations on the use of distributors (ME -Microenterprise and EPP – Small Business Enterprise) to participate in bids; requires a “letter of solidarity” from the manufacturer, guaranteeing the availability of the product for delivery, and starts to consider life cycle value (parts, maintenance, and hardware). On the other hand, he emphasized, it establishes an efficiency contract and provides savings, and defines the compliance policy as a true commandment (value) or competitive advantage (enablement / penalty).

Link to the study presentation: https://www.youtube.com/@abimed8617/videos